Latest Articlesddd
The uncontrolled blowing toxic wind contaminates this country’s environment, it brings down the oversold scientifically solid …
While waiting for Mueller’s report we stopped speculating on the stocks in what we saw as …
Governor Cooper to cut ribbon on bluebird bio facility Bluebird bio (BLUE) announced today, in its …
Biogen’s (BIIB) decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE which is designed …
News We Loved to Hear The First and Only Approval of a Specific Product for Postpartum …
The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week …
Prohost Letter #429 End of the Year Decisions ~ Part 4 We picked for our portfolio …
Atossa Genetics (ATOS) announced that the FDA has issued a “Safe to Proceed” letter under their “expanded …
We love to read news about gene therapy as it is the only possibility for curing …
Thanks to abundant cabozantinib sales’ revenues Exelixis (EXEL) is advancing a new generation of its medicines …
The Week in Review #38 SYNOPSIS Good News and Setbacks During the Departed Week from the …
CRISPR Therapeutics' (CRSP) stock added around $8 today while reporting financial results for the fourth quarter …
We congratulate our subscribers who kept Spark Therapeutics (ONCE) in spite of the stock’s kind of paralysis for no …
Cytokinetics’ (CYTK) investigational product omecamtiv mecarbil, the firm’s potential treatment for heart failure with reduced ejection fraction, …
Keytruda and Cabometyx Are Both Winners Keytruda failed to meet co-primary endpoints in Pivotal Phase 3 …
From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation …
Today, at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (GU) held at …
RegenxBio (RGNX), a clinical-stage gene therapy firm with a proprietary NAV® Technology Platform, will host an analyst and investor …
Exelixis’ (EXEL) financial results for the fourth quarter and full year 2018 are as inspiring as they are …
Portola Pharmaceuticals (PTLA) announced full results from ANNEXA-4, Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa® in …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
